The low activity of TMZ in patients with MGMT‐unmethylated GBM prompted selective clinical trials for this subgroup, allowing the comparison of experimental treatment arms to placebo without TMZ in the standard arm [42, 44]. This evidence concerns the gene MGMT and glioblastoma.